View in EDS

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

Saved in:
Bibliographic Details
Title: Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.
Authors: Aggarwal R; Division of Hematology/Oncology, University of California, San Francisco, California., Italiano A; Department of Medicine, Institut Bergonié, Bordeaux, France.; Faculty of Medicine, University of Bordeaux, Bordeaux, France., Domchek SM; Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania., Goodman O; Hematology/Oncology, Nevada Oncology Specialists, Las Vegas, Nevada., Postel-Vinay S; Drug Development Department, U981 INSERM Research Unit, Institut Gustave Roussy, Villejuif, France.; Cancer Institute, University College of London, London, United Kingdom., Garcia-Donas J; Gynecologic and Genitourinary Tumors, HM Hospitales - Centro Integral Oncológico HM Clara Campal, Madrid, Spain., Dorff T; Genitourinary Disease Program, City of Hope Comprehensive Cancer Center, Duarte, California., Reichert ZR; University of Michigan, Rogel Comprehensive Cancer Center, Ann Arbor, Michigan., Vinceneux A; Medical Oncology, Centre Léon Bérard, Lyon, France., Shore N; START Carolinas/Carolina Urologic Research Center, Myrtle Beach, South Carolina., Marshall CH; Oncology, Johns Hopkins University, Baltimore, Maryland., Armenia J; Oncology Data Science, AstraZeneca, Cambridge, United Kingdom., Parr G; Oncology Early Development Clinical, AstraZeneca, Cambridge, United Kingdom., Kmieciak A; Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Cambridge, United Kingdom., Lukashchuk N; Translational Medicine, AstraZeneca, Cambridge, United Kingdom., Murina O; Translational Medicine, AstraZeneca, Cambridge, United Kingdom., Slade D; Statistical Science, AstraZeneca, Cambridge, United Kingdom., Shah N; Oncology Early Development Clinical, AstraZeneca, Waltham, Massachusetts., Loembé B; Oncology Early Development Clinical, AstraZeneca, Cambridge, United Kingdom., Dean E; Oncology Early Development, AstraZeneca, Cambridge, United Kingdom., Sanai E; Oncology Early Development Clinical, AstraZeneca, Cambridge, United Kingdom., Abida W; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Source: Cancer research communications [Cancer Res Commun] 2026 Jul 01; Vol. 6 (7), pp. 1546-1556.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2767-9764
DOI:10.1158/2767-9764.CRC-26-0184